期刊
LUPUS
卷 19, 期 4, 页码 406-411出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/0961203309360808
关键词
anticardiolipin antibody; antiphospholipid syndrome; beta 2-glycoprotein I; cerebrovascular disease; lupus anticoagulant; thrombosis
类别
资金
- NICHD NIH HHS [K12 HD041648-07] Funding Source: Medline
- NINDS NIH HHS [L40 NS063883-02] Funding Source: Medline
The most common neurological manifestations of antiphospholipid syndrome (APS) in all age-groups include stroke and transient ischemic attacks due to arterial thromboses and cerebral ischemia. Antiphospholipid antibodies may cause additional non-criteria neurological impairments through vascular, neuroinflammatory and direct neuronal effects. Anti-aggregant or anticoagulant therapies are indicated for APS-related ischemic strokes. Treatment regimens for asymptomatic antibody-positive patients and those with refractory or recurrent disease remain controversial. There is scant literature on the epidemiology and therapy of neurological APS manifestations in pediatric patients. Assessments of modifiable cardiovascular and inherited thrombophilia risk factors are essential in patients with APS. There may be a role for novel neuroimaging modalities in quantifying APS-related microstructural brain damage. The clinical utility of statins, antimalarials, angiotensin-converting enzyme inhibitors, and thrombin inhibitors warrant further research. Lupus (2010) 19, 406-411.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据